23-Jul-2026
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
PRNewswire (Thu, 23-Jul 4:05 PM ET)
Morgan Stanley Issues a Hold Rating on Neurocrine (NBIX)
TipRanks (Thu, 23-Jul 8:56 AM ET)
Key FDA drugs advisory committee to be reconstituted
Seeking Alpha News (Wed, 22-Jul 9:49 AM ET)
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
PRNewswire (Tue, 21-Jul 4:05 PM ET)
Bank of America leads Oppenheimer's latest buy additions with near-perfect Quant rating
Seeking Alpha News (Tue, 21-Jul 6:58 AM ET)
Top buy and sell ideas within each sector – Oppenheimer
Seeking Alpha News (Mon, 20-Jul 2:59 PM ET)
PRNewswire (Thu, 9-Jul 4:01 PM ET)
PRNewswire (Wed, 1-Jul 4:05 PM ET)
PRNewswire (Mon, 15-Jun 4:11 PM ET)
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Neurocrine Biosciences trades on the NASDAQ stock market under the symbol NBIX.
As of July 23, 2026, NBIX stock price climbed to $174.15 with 1,020,358 million shares trading.
NBIX has a beta of 0.59, meaning it tends to be less sensitive to market movements. NBIX has a correlation of 0.06 to the broad based SPY ETF.
NBIX has a market cap of $17.52 billion. This is considered a Large Cap stock.
Last quarter Neurocrine Biosciences reported $814 million in Revenue and $1.94 earnings per share. This beat revenue expectation by $51 million and exceeded earnings estimates by $.33.
In the last 3 years, NBIX traded as high as $181.18 and as low as $84.23.
The top ETF exchange traded funds that NBIX belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.
NBIX has outperformed the market in the last year with a return of +31.2%, while the SPY ETF gained +18.6%. In the last 3 month period, NBIX beat the market returning +32.8%, while SPY returned +4.1%. However, in the most recent 2 weeks NBIX has underperformed the stock market by returning -2.3%, while SPY returned -1.0%.
NBIX support price is $169.32 and resistance is $176.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBIX shares will trade within this expected range on the day.